Simple preparation of76Br,123I and211At labeled 5-halo-2′-deoxyuridine by Koziorowski, J. & Weinreich, R.
LETTER TO THE EDITOR 
Journal of Radioanalytical nd Nuclear Chemistry, Vol. 219, No. 1 (1997) 127-128 
Simple preparation of 7 Br, 1231 and mAt labeled 5-halo-2'-deoxyuridine 
J. Koziorowski, 1,2 R. Weinreich 1. 
l lnstitute for Mea~cal Radiobiology, Paul Scherrer Institute, CH-5232 Villigen PSI, Switzerland 
21nstitute of Chemistry, Department ofOrganic Chemistry, Box 531, S-751 21 Uppsala, Sweden 
(Received January 20, 1997) 
A fast and easy method for the preparation of radiolabeled 5-halo-2"-deoxyuridine (halo= [76Br], [1231] and [211At]) is presented. Labeling is 
accomplished by oxidation of the halogenide with Iodogen for [123I] and [211At], and Chloramine-T (CAT) for [76Br] followed by halodestannylation of 
5-trimethylstannyl-2'-deoxyuridine (TMSUdR). The reaction takes 1 minute giving > 900 yield for all three halogens. 
Introduction 
The radiolabeled 5-bromo/iodo/astato-2"-deoxyuridines 
([76Br]BrUdR, [lZ3I]IUdR, [211At]AtUdR) are thymidine 
(TdR) analogs where the 5-methyl group has been replaced 
with the above mentioned nuclides. Due to their similarity 
with TdR they are phosphorylated and incorporated into the 
DNA of proliferating cells in S-phase. Furthermore, as a 
result of the different decay properties of the three 
radiohalogens, the corresponding 5-halo-2"-deoxyuridine 
will be suitable for various applications: 76Br has a 16.1-hour 
half-life and decays emitting 13+-radiation (57%) of various 
energies, 123I presents a 13.1-hour half-life, mainly (83%) 
emitting 159 keV "t-radiation. Finally, the 7.2-hour half-life 
a-particle mitter 2nAt, displays two decay branches where 
the first produces (42%) 5.87 MeV a-particles and the 
second (58%) leads to 211po by electron capture, with 0.52- 
second half-life, which decays by the emission of 7.45 MeV 
t~-particles. Whereas 5-[211At]astato-2'-deoxyuridine has 
potential as an endoradiotherapeutic agent, 1 both 
5-[76Br]bromo - and 5-[123I]iodo-2"-deoxyuridine possess 
properties making them suitable for the measurement of cell 
proliferation by imaging, in diagnostic oncology. 2,3 Herein, 
we report a simple method for the preparation of5-trimethyl- 
stannyl-2"-deoxyuridine (TMSUdR), and the subsequent 
labeling with [76Br], [1231] and ['211At]. 
Experimental 
General 
The radionuclides were all produced at the Paul 
Scherrer Institute (PSI) via the following nuclear reactions: 
natBr(p,xn)76Kr-->76Br 
127I(p,5n) 123Xe--h123I 
209Bi(t~,2n) 11At 
Ep = 72 MeV 
Ep = 72 MeV 
E a = 28 MeV 
All chemicals except Iodogen, which was purchased 
from Pierce, were purchased from Fluka and used without 
further purification. 1H NMR spectra were recorded on a 
Varian Gemini 2000 300 MHz spectrometer. HPLC was 
conducted using a Waters 501 pump, a Waters 440 
fixed-wavelength u.v. detector (254 nm), and a NaI(TI) 
crystal detector. HPLC analyses were performed on a C-18 
(10 ~tm; 4.6 mm x 250 mm) column eluted with 80 : 20 
(v : v) water : methanol at 1 ml/min flow rate. TLC was 
carded out on precoated silica gel 60 F254 on glass 
(Merck), with 80 : 20 (v : v) dichloromethane : methanol 
as mobile phase. The TLC-plates were examined on an 
Berthold gas-flow scanner. Preparative column flash 
chromatography was accomplished with Silica gel 60, 
230-400 mesh ASTM (Merck). 
Preparation of 5-trimethylstannyl-2"-deoxyuridine 
(TMSUdR) 
5-Trimethylstannyl-2"-deoxyuridine was prepared using a 
slightly modified procedure of WmERn~c~ etal, 4 A mixture 
of IUdR (1 g, 2.8 mmol), hexamethyldistannane (1.3 ml, 
2 g, 6.1 mmol) and bis(triphenylphosphine)- 
palladium(II)dichloride (100 mg) in anhydrous 1.4-dioxane 
(50 ml) was stirred at 60 ~ for 2 hours under an atmosphere 
of dry nitrogen. After evaporation ofdioxane the residue was 
dissolved in acetonitrile and washed several times with 
cyclohexane to remove the tin residue. The acetonitrile 
solution was filtered, the solvent removed in vacuum and the 
crude product was purified by flash chromatography using a 
dichloromethane 9 methanol gradient (100% dichloro- 
methanes90% dichloromethane : 10% methanol) to yield 
0.62 g, 57% of TMSUdR as white translucent crystals. 1H 
NMR (DMSO-de) data were in agreement with a previous 
report: 4 ~ 0.72 (s, 9 H, Me3Sn), 2.62 (m, 1 H, H-2"), 4.08 (t, 
2 H, H-5') 4.31 (m, 1 H, H-4'), 4.78 (m, 1 H, H-3"), 5.48 (t, 
1 H, Y-OH), 5.72 (d, 1 H, 3'-OI-I), 6.70 (t, 1 H, H-I'), 8.15 
(s, 1 H, H-6). 
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Preparation of 5-[ml]iodo - 
and 5-[2n At]astato-2'-deoxyuridine 
10 gl of a Iodogen stock solution (1 mg/1 ml in dry 
dichloromethane) was placed in a 0.3 ml Reacti-Vial 
(Pierce). The solvent was evaporated by a slow stream of 
dry nitrogen, leaving a thin coat of Iodogen. 10 lxl of an 
aqueous TMSUdR solution (1 mg/ml) was added followed 
by 10 lal of either [123I]-iodide, no-carrier added (n.c.a.) or 
[2XlAt]-astatide (n.c.a.) in a 0.1M sodium chloride (0.1M 
phosphate buffer pH 7. The reaction mixture was vortexed 
for 1 minute yielding > 90% of the corresponding product. 
Radio TLC Rf: At- 0.1, AtUdR 0.55, I- 0.2, IUdR 0.55. 
HPLC retention times (Rt) : I- 4 min, UdR 5.5 min, IUdR 
9 min. 
well-known oxidant CAT, while attempts o use iodogen as 
oxidant were unsuccessful. Some more recent reports on 
the preparation of 5-radiobromo-2"-deoxyuridine 6,7 give 
50--65% radiochemical yield, while an earlier 
investigation s describes a labeling technique producing 
80-90% radiochemical yield of the radiobromonucleoside: 
bromodestannylation s less laborious than the three-step 
procedure described in the last mentioned publication, and 
gives slightly higher yields. We found that mdiolabeled 
5-halo-2'-deoxyuridine ([76Br], [123I] and [211At]) can be 
prepared in a simple and rapid way by destannylation f 
TMSUdR. The simplicity can contribute to a reliable 
production in a clinical situation, while the short labeling 
time might decrease radiolysis and reduce personnel dose. 
Preparation of 5-176Br]bromo-2"-deoxyuridine 
To a 0.3 ml Reacti-Vial (Pierce) was pipetted 10 ~tl 
[76Br]bromide (n.c.a.) in a 0.1M sodium chloride/0.1M 
phosphate buffer pH 7 solution and 10 l.tl of an aqueous 
TMSUdR solution (1 mg/ml) followed by 10 tal of a CAT 
solution (2 mg]ml in 0.1M pH 7 phosphate buffer). The 
reaction mixture was vortexed for 1 min yielding > 90% 
of the product. Radio TLC Rt: Br- 0.2, BrUdR 0.55. 
HPLC R~: Br-4 min, UdR 5.5 min, BrUdR 9 min. 
Results and discussion 
In the first report where crystalline TMSUdR was 
obtained, l the route involved a two-step purification 
including silica gel preparative TLC. Our approach is a 
one-step method, and consequently presents a less 
time-consuming and circumstantial route to obtain 
TMSUdR in solid form. Both the 5-[123I]iodo - and 
5-[2HAt]astato-2"-deoxyuridine syntheses have been 
described. 1.5 Our approach did not improve the yield, but 
the use of Iodogen-coated vials which can be stored for 
long times versus a heterogeneous mixture reaction, 
depending on the freshness of the non-stable oxidizing 
reagent should improve reproducibility and reliability. 
Bromodestannylation was accomplished using the 
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